e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
New data on established treatments for COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients
Edward Kerwin (Medford, United States of America), Edward Kerwin, Thomas Siler, Lee Tombs, Ana R. Sousa, Karen Singletary, Alison Church
Source:
International Congress 2015 – New data on established treatments for COPD
Session:
New data on established treatments for COPD
Session type:
Poster Discussion
Number:
1490
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Edward Kerwin (Medford, United States of America), Edward Kerwin, Thomas Siler, Lee Tombs, Ana R. Sousa, Karen Singletary, Alison Church. Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients. Eur Respir J 2015; 46: Suppl. 59, 1490
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021
Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Efficacy of an inhaled corticosteroid/long-acting ?2-agonist combination in symptomatic COPD patients in GOLD groups B and D
Source: Eur Respir J 2015; 46: 255-258
Year: 2015
Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe-to-very severe COPD
Source: Annual Congress 2005 - Therapeutic options for COPD: present and future
Year: 2005
Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta
2
-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Year: 2015
Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Once-daily QVA149 improves lung function and health status versus twice-daily salmeterol/fluticasone (SFC) in symptomatic GOLD B and GOLD D COPD patients: LANTERN/ILLUMINATE pooled analysis
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004
Once-daily indacaterol 150µg or 300µg and other bronchodilators in COPD patients of GOLD 2011 groups A and B
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
TIOSPIR®: Large scale trial of tiotropium Respimat® vs HandiHaler® (HH) in patients (pts) with COPD
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017
Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD
Source: International Congress 2014 – Markers
Year: 2014
Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD)
Source: Eur Respir J 2004; 24: Suppl. 48, 252s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept